drugset
drugset / Trial / NCT03890770

A Study to Assess the Safety of Experimental Medication BMS986165 in Participants With Normal Kidney Function and Participants With Mild to End-Stage Kidney Disease.

NCT03890770 ↗

Phase 1 Completed 44 enrolled Bristol-Myers Squibb
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to investigate BMS-986165 in participants with different levels of kidney function.

Timeline

Start
2019-04-04
Primary completion
2020-02-07
Completion
2020-02-13

Drugs

EvaluationDrugModalityDoseRoute
Subject CRAVACITINIB Small molecule — —

Indications

impaired renal function disease